ResearcherChristian-Albrechts-Universität zu KielNo recent work listed

Ulf Martin Geisen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6583-460X; OpenAlex author ID A5077616533. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2015: 2 papers

Papers 2

Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Co-author DOI 10.1002/ijc.29445 ↗
Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells. Co-author DOI 10.3390/md13074470 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Holger Kalthoff · 2 shared papers, 2015 · strength 0.09
- Paper Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic C… DOI 10.3390/md13074470 ↗
- Paper Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models… DOI 10.1002/ijc.29445 ↗
Reinhild Holmer · 1 shared paper, 2015 · strength 0.04
- Paper Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models… DOI 10.1002/ijc.29445 ↗
Freya A. Goumas · 1 shared paper, 2015 · strength 0.04
- Paper Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models… DOI 10.1002/ijc.29445 ↗
Karen Legler · 1 shared paper, 2015 · strength 0.04
- Paper Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models… DOI 10.1002/ijc.29445 ↗
Christoph Röcken · 1 shared paper, 2015 · strength 0.04
- Paper Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models… DOI 10.1002/ijc.29445 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.